IMBdx, Inc. engages in the development of liquid biopsy tests for cancer diagnosis. It focuses on the following business areas: diagnosis and treatment of advanced cancer, early detection of recurrence after surgery, and early cancer diagnosis. Its products include AlphaLiquid, CancerDetect, and CancerFind. The company was founded by Tae-Yu Kim, Sung-Tae Moon, and Doo-Hee Bang on July 5, 2018 and is headquartered in Seoul, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company